{"nctId":"NCT01959841","briefTitle":"Phase III Study of ASP2151 in Herpes Zoster Patients","startDateStruct":{"date":"2013-08"},"conditions":["Herpes Zoster"],"count":751,"armGroups":[{"label":"ASP2151(200 mg)","type":"EXPERIMENTAL","interventionNames":["Drug: ASP2151"]},{"label":"ASP2151(400mg)","type":"EXPERIMENTAL","interventionNames":["Drug: ASP2151"]},{"label":"valaciclovir","type":"EXPERIMENTAL","interventionNames":["Drug: valaciclovir"]}],"interventions":[{"name":"ASP2151","otherNames":[]},{"name":"valaciclovir","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n(1) Patients who have a rash associated with herpes zoster, and who can start receiving the study drug within 72 hours after onset of the rash\n\nExclusion Criteria:\n\n1. Patients who are not expected to have an adequate response to oral antiviral medication\n2. An extreme decline in immune function\n3. Presence of serious complications\n4. Patients found to meet any of the following conditions based on laboratory tests performed within 14 days before informed consent:\n\n   * AST or ALT ≥ 2.5 x upper limit of normal\n   * Platelet count \\< lower limit of normal\n   * Serum creatinine ≥ 1.5 mg/dL\n   * Creatinine clearance \\< 50 mL/min\n5. Current or previous history of malignant tumor within 5 years before informed consent\n6. Diagnosis of autoimmune disease\n7. Evidence of bone marrow suppression","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"79 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Percentage of Participants Achieving Cessation of New Lesion Formation by Day 4 of Study Treatment","description":"The investigator assessed the Number of rashes (erythemas/papulae and vesicles/pustules). The \"new lesion formation\" was defined as the state in which the number of rashes is increasing.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.6","spread":null},{"groupId":"OG001","value":"81.1","spread":null},{"groupId":"OG002","value":"75.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Cessation of New Lesion Formation","description":"The investigator assessed the Number of rashes (erythemas/papulae and vesicles/pustules). The \"new lesion formation\" was defined as the state in which the number of rashes is increasing.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Complete Crusting","description":"We defined the following state as \"Complete crusting\".\n\n1. A condition where all lesions of erythemas/papulae, vesicles/pustules, and erosions/ulcers have disappeared, and all rashes are crusted (epithelialization of the base of crusts is not required).\n2. In subjects with no formation of vesicles or pustules, a condition where all lesions of erythemas/papulae have disappeared.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Healing","description":"We defined the following state as \"Healing\".\n\n1. A condition where all lesions of erythemas/papulae, vesicles/pustules, and erosions/ulcers have disappeared, and complete disappearance of crusts or complete epithelialization of the base of crusts are considered to have been achieved.\n2. In subjects with no formation of vesicles or pustules, a condition where all lesions of erythemas/papulae have disappeared","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Pain Resolution","description":"Investigators assessed the pain using NRS. The date of pain resolution is defined as the first day when all NRS scores are rated as 2 or less, and such scores are continuously observed until Day 92 or discontinuation visit.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Virus Disappearance","description":"Virus desiappearance was defined as the participants who who reached virus-negative status according to the virus isolation and culture assay or whose samples were not available because of complete crusting or healing","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":252},"commonTop":["Nasopharyngitis","Alpha 1 microglobulin increased","Beta-N-acetyl-D-glucosaminidase increased","Fibrin degradation products increased","Headache"]}}}